Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?

P. Raanani*, Y. Shasha, C. Perry, U. Metser, E. Naparstek, S. Apter, A. Nagler, A. Polliack, I. Ben-Bassat, E. Even-Sapir

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review


Background: The clinical impact of fused PET/CT data on staging and patient management of Hodgkin disease (HD) and non-Hodgkin lymphoma (NHL) was assessed. Patients and methods: A total of 103 consecutive patients with newly diagnosed NHL (n = 68) and HD (n = 35) were assessed retrospectively. Three comparisons were carried out in an attempt to assess the added value of each modality. Results: For NHL patients, there were significant differences between staging by CT versus PET/CT (P = 0.0001). Disease was upstaged by PET/CT in 31% (mostly in stages I and II) and downstaged in only 1% of patients. In 25% of the patients, the treatment approach was changed according to CT versus PET/CT findings. For HD patients, disease was upstaged by PET/CT in 32% and downstaged by PET/CT in 15% (P = NS). As for NHL, upstaging by PET/CT versus CT was evident mostly for stages I and II. The treatment strategy was altered as determined by CT versus PET/CT in 45% of the patients. Conclusions: The addition of PET/CT to CT changed the management decisions in approximately a quarter of NHL and a third of HD patients, mostly in early disease stages. Thus, PET/CT performed as the initial staging procedure may well obviate the need for additional diagnostic CT in the majority of patients.

Original languageEnglish
Pages (from-to)117-122
Number of pages6
JournalAnnals of Oncology
Issue number1
StatePublished - Jan 2006


  • Hodgkin disease
  • Non-Hodgkin lymphoma
  • PET/CT
  • Staging


Dive into the research topics of 'Is CT scan still necessary for staging in Hodgkin and non-Hodgkin lymphoma patients in the PET/CT era?'. Together they form a unique fingerprint.

Cite this